Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.

Publication/Presentation Date

7-1-2023

Abstract

Hypertension is a global epidemic, affecting around 30.4% of the population and being the leading preventable risk factor for death. Despite the availability of numerous antihypertensive agents, less than 20% of individuals have their blood pressure controlled. Resistant hypertension poses a challenge, but a new class of medication, aldosterone synthase inhibitors (ASI), shows promise. ASI reduces aldosterone production by inhibiting aldosterone synthase. This review article focuses on Baxdrostat, a highly potent ASI currently in phase 3 trials. It discusses the drug's biochemical pathway, efficacy trials in animals and humans, and its potential in uncontrolled hypertension, chronic kidney disease, and primary aldosteronism.

First Page

101918

Last Page

101918

ISSN

1535-6280

Disciplines

Medicine and Health Sciences

PubMedID

37399857

Department(s)

Department of Medicine, Cardiology Division, Department of Medicine Fellows and Residents, Fellows and Residents

Document Type

Article

Share

COinS